Ilaprazole, a new proton pump inhibitor, is primarily metabolized to ilaprazole sulfone by CYP3A4 and 3A5
- 29 September 2011
- journal article
- Published by Taylor & Francis in Xenobiotica
- Vol. 42 (3), 278-284
- https://doi.org/10.3109/00498254.2011.622416
Abstract
Ilaprazole is a new proton pump inhibitor, designed for treatment of gastric ulcers, and developed by Il-Yang Pharmaceutical Co (Seoul, Korea). It is extensively metabolised to the major metabolite ilaprazole sulfone. In the present study, several in vitro approaches were used to identify the cytochrome P450 (CYP) enzymes responsible for ilaprazole sulfone formation. Concentrations of ilaprazole sulfone were determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Incubation of ilaprazole with cDNA-expressed recombinant CYPs indicated that CYP3A was the major enzyme that catalyses ilaprozole to ilaprazole sulfone. This reaction was inhibited significantly by ketoconazole, a CYP3A inhibitor, and azamulin, a mechanism-based inhibitor of CYP3A, while no substantial effect was observed using selective inhibitors for eight other P450s (CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP2E1). In addition, the formation of ilaprazole sulfone correlated well with CYP3A-catalysed testosterone 6β-hydroxylation and midazolam 1′-hydroxylation in 20 different human liver microsome panels. The intrinsic clearance of the formation of ilaprazole sulfone by CYP3A4 was 16-fold higher than that by CYP3A5. Collectively, these results indicate that the formation of the major metabolite of ilaprazole, ilaprazole sulfone, is predominantly catalysed by CYP3A4/5.Keywords
This publication has 23 references indexed in Scilit:
- Clopidogrel–Drug InteractionsJournal of the American College of Cardiology, 2011
- Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in EthiopiansThe Pharmacogenomics Journal, 2010
- In vitrometabolism of a novel PPARγagonist, KR-62980, and its stereoisomer, KR-63198, in human liver microsomes and by recombinant cytochrome P450sXenobiotica, 2008
- Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problemInt. Journal of Clinical Pharmacology and Therapeutics, 2006
- Degradation of lansoprazole and omeprazole in the aquatic environmentChemosphere, 2006
- High‐throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometryRapid Communications in Mass Spectrometry, 2005
- STEREOSELECTIVE METABOLISM OF LANSOPRAZOLE BY HUMAN LIVER CYTOCHROME P450 ENZYMESDrug Metabolism and Disposition, 2003
- Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazoleBritish Journal of Clinical Pharmacology, 1998
- A convenient method to discriminate between cytochrome P450 enzymes and flavin-containing monooxygenases in human liver microsomesArchives of Toxicology, 1996
- Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9Xenobiotica, 1995